This session introduces new frontiers in transcatheter aortic valve implantation (TAVI), including artificial intelligence-enabled systems and minimalist, radiation-free approaches guided by echocardiography. It covers complex procedural techniques such as axillary access under TEE guidance, precision snaring, and managing challenging anatomies, emphasizing advancements in safety and efficacy...

This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...

This session explores the role of artificial intelligence in imaging and the cathlab, emphasizing computer vision applications distinct from language models. It discusses AI's integration into procedural planning and guidance, balancing algorithmic support with physician judgement to enhance interventional cardiology workflows.

This session emphasizes critical imaging aspects necessary for assessing calcified coronary lesions. It addresses lesion-specific Agatston scoring, OCT-guided PCI optimization, coronary CT planning, histopathological insights, and predictors of stent underexpansion after calcium modification.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.